A BILL 
To amend the Public Health Service Act to increase the 
transparency of pharmaceutical research costs, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pharmaceutical Re-
4
search Transparency Act of 2022’’. 
5
22:05 Apr 08, 2022
H7474
2 
•HR 7474 IH
SEC. 2. EXPANSION OF REGISTRY AND RESULTS DATA 
1
BANK TO INCLUDE COSTS OF DRUG CLINICAL 
2
TRIALS. 
3
(a) IN GENERAL.—Section 402(j) of the Public 
4
Health Service Act (42 U.S.C. 282(j)) is amended— 
5
(1) by redesignating paragraph (7) as para-
6
graph (8); and 
7
(2) by inserting after paragraph (6) the fol-
8
lowing new paragraph: 
9
‘‘(7) CREATION OF CLINICAL TRIAL COST DATA 
10
REPOSITORY.— 
11
‘‘(A) GENERALLY.—The Secretary, acting 
12
through the Director of NIH, shall create a 
13
publicly available Federal website to serve as a 
14
repository of cost data for all applicable drug 
15
clinical trials (in this paragraph referred to as 
16
the ‘cost data repository’). Such repository shall 
17
be searchable by the following criteria: 
18
‘‘(i) The responsible party or sponsor 
19
of the applicable drug clinical trial, or any 
20
entity funding the applicable drug clinical 
21
trial. 
22
‘‘(ii) The name of the intervention, in-
23
cluding any drug being studied in the ap-
24
plicable drug clinical trial. 
25
22:05 Apr 08, 2022
H7474
3 
•HR 7474 IH
‘‘(iii) The study phase of the applica-
1
ble drug clinical trial. 
2
‘‘(iv) The start date and completion 
3
date of the applicable drug clinical trial. 
4
‘‘(v) Such other criteria as the Sec-
5
retary deems appropriate. 
6
‘‘(B) COST DATA DEFINED.—For purposes 
7
of this paragraph, the term ‘cost data’ includes 
8
the following information: 
9
‘‘(i) The total cost of the applicable 
10
drug clinical trial. 
11
‘‘(ii) The cost of the trial per patient. 
12
‘‘(iii) Expenditures for each of the fol-
13
lowing categories: 
14
‘‘(I) Personnel. 
15
‘‘(II) Any intervention or treat-
16
ment that is administered in one or 
17
more arms of the applicable drug clin-
18
ical trial. 
19
‘‘(III) Materials and supplies. 
20
‘‘(IV) Health care services pro-
21
vided to subjects. 
22
‘‘(V) Site management. 
23
‘‘(VI) Laboratory. 
24
‘‘(VII) Equipment. 
25
22:05 Apr 08, 2022
H7474
4 
•HR 7474 IH
‘‘(VIII) The allocable portion of 
1
any facilities costs, administrative 
2
costs, or other costs that are not sole-
3
ly attributable to the applicable drug 
4
clinical trial. 
5
‘‘(IX) Such other categories as 
6
the Secretary may identify by regula-
7
tion. 
8
‘‘(C) POSTING OF CLINICAL TRIAL COST 
9
DATA.— 
10
‘‘(i) IN
GENERAL.—Except as pro-
11
vided in clause (iii), each responsible party 
12
of an applicable drug clinical trial shall 
13
post cost data for that trial to the cost 
14
data repository no later than 1 year after 
15
the completion date of the trial. 
16
‘‘(ii) FORMAT AND METHODOLOGY OF 
17
18
clause (i) shall— 
19
‘‘(I) 
include 
individual 
data 
20
points for the information required 
21
under 
subparagraphs 
(B)(i) 
and 
22
(B)(ii), separated by year; 
23
‘‘(II) 
include 
individual 
data 
24
points for each category listed under 
25
22:05 Apr 08, 2022
H7474
5 
•HR 7474 IH
subparagraph (B)(iii), separated by 
1
year; 
2
‘‘(III) limit the cost of the inter-
3
vention or treatment under subpara-
4
graph (B)(iii)(II) to manufacturing 
5
costs unless the responsible party of 
6
the trial was required to purchase the 
7
intervention or treatment from an un-
8
affiliated third party; 
9
‘‘(IV) 
include 
detailed 
docu-
10
mentation and methodology for the 
11
calculation of costs identified under 
12
subparagraph (B)(iii)(VIII); and 
13
‘‘(V) include a signed certifi-
14
cation that the posted data is com-
15
plete and accurate. 
16
‘‘(iii) DELAYED
OF
COST 
17
DATA AND EXTENSIONS.— 
18
‘‘(I) SEEKING INITIAL APPROVAL 
19
OF DRUG, OR APPROVAL OF A NEW 
20
USE.—If the responsible party for an 
21
applicable drug clinical trial submits a 
22
certification that paragraph (3)(E)(iv) 
23
or paragraph (3)(E)(v) applies to 
24
such trial, the responsible party shall 
25
22:05 Apr 08, 2022
H7474
6 
•HR 7474 IH
post cost data under clause (i) at the 
1
time that clinical trial information is 
2
required to be submitted under the 
3
applicable paragraph. 
4
‘‘(II) 
EXTENSION
FOR
GOOD 
5
CAUSE.—The Director of NIH may 
6
provide an extension of the deadline 
7
for posting of cost data under clause 
8
(i) if the responsible party for the 
9
trial submits to the Director a written 
10
request that demonstrates good cause 
11
for the extension and provides an esti-
12
mate of the date on which the infor-
13
mation will be posted. The Director of 
14
NIH may grant more than one such 
15
extension for a clinical trial, but 
16
under no circumstances shall an ex-
17
tension under this subclause extend 
18
beyond the date that is 18 months 
19
after the completion date of the trial. 
20
‘‘(III) EXTENSION TO ESTABLISH 
21
NECESSARY
INFRASTRUCTURE.—If 
22
necessary to establish the necessary 
23
infrastructure to accept, organize, and 
24
post cost data submitted under clause 
25
22:05 Apr 08, 2022
H7474
7 
•HR 7474 IH
(i), the Director of NIH may extend 
1
the deadline for the posting of cost 
2
data under clause (i) to not later than 
3
2 years after the date of enactment of 
4
the Pharmaceutical Research Trans-
5
parency Act of 2022. 
6
‘‘(IV) 
RULE
OF
CONSTRUC-
7
TION.—This clause shall not be con-
8
strued to have any effect on reporting 
9
obligations of the responsible party 
10
under provisions other than this para-
11
graph. 
12
‘‘(D) LINKING
TO
COST
DATA
REPOSI-
13
TORY.— 
14
‘‘(i) CREATION OF FIELD.—The Di-
15
rector of NIH shall create a field within 
16
the registry and results data bank to in-
17
clude an electronic link to the relevant cost 
18
data posting under subparagraph (C)(i). 
19
‘‘(ii) POSTING.—The responsible party 
20
for an applicable drug clinical trial shall 
21
post in the field created under clause (i) a 
22
link to the relevant cost data posting no 
23
later than 5 days after initial posting of 
24
the cost data under subparagraph (C)(i). 
25
22:05 Apr 08, 2022
H7474
8 
•HR 7474 IH
‘‘(E) RULEMAKING.— 
1
‘‘(i) IN
GENERAL.—The Secretary 
2
shall promulgate regulations to carry out 
3
this paragraph that include— 
4
‘‘(I) definitions for each category 
5
of information identified in subpara-
6
graph (B); 
7
‘‘(II) standards for allocating 
8
fixed expenditures across multiple 
9
years of an applicable drug clinical 
10
trial; 
11
‘‘(III) a standard format for the 
12
submission and posting of cost data 
13
under this paragraph; 
14
‘‘(IV) procedures, standards, and 
15
requirements for the reporting docu-
16
mentation and methodology required 
17
under subparagraph (C)(ii)(IV); and 
18
‘‘(V) 
any 
other 
procedures, 
19
standards, or requirements necessary 
20
to ensure public transparency of cost 
21
data as required by this paragraph. 
22
‘‘(ii) 
INITIAL
REGULATIONS.—The 
23
Secretary shall— 
24
22:05 Apr 08, 2022
H7474
9 
•HR 7474 IH
‘‘(I) not later than one year after 
1
the date of enactment of the Pharma-
2
ceutical Research Transparency Act of 
3
2022, 
propose 
initial 
regulations 
4
under clause (i); and 
5
‘‘(II) not later than 2 years after 
6
such date of enactment, finalize such 
7
regulations. 
8
‘‘(F) APPLICABILITY.—The requirements 
9
of this paragraph apply only to applicable drug 
10
clinical trials with a start date on or after the 
11
date of enactment of the Pharmaceutical Re-
12
search Transparency Act of 2022.’’. 
13
(b) CONFORMING CHANGES.—Section 402(j) of the 
14
Public Health Service Act (42 U.S.C. 282(j)), as amended 
15
by subsection (a), is further amended— 
16
(1) in paragraph (1)(A)(iv), by striking ‘‘para-
17
graph (2) or under paragraph (3)’’ and inserting 
18
‘‘paragraph (2), (3), or (7)’’; 
19
(2) in paragraph (4)— 
20
(A) in subparagraph (A), by striking 
21
‘‘paragraph (2) or paragraph (3)’’ and inserting 
22
‘‘paragraph (2), (3), or (7)’’; and 
23
(B) in subparagraph (B)(i), by striking 
24
‘‘paragraphs (2) and (3)’’ each place it appears 
25
22:05 Apr 08, 2022
H7474
10 
•HR 7474 IH
and inserting ‘‘paragraphs (2), (3), and (7)’’; 
1
and 
2
(3) in paragraph (5)— 
3
(A) in subparagraph (A), by striking 
4
‘‘paragraphs (2) and (3)’’ each place it appears 
5
and inserting ‘‘paragraphs (2), (3), and (7)’’; 
6
and 
7
(B) in subparagraph (E)(i), by striking 
8
‘‘paragraphs (2) or (3)’’ and inserting ‘‘para-
9
graph (2), (3), or (7)’’. 
10
SEC. 3. DISCLOSURE OF RESEARCH AND DEVELOPMENT 
11
EXPENDITURES BY DRUG MANUFACTURERS. 
12
Section 13 of the Securities Exchange Act of 1934 
13
(15 U.S.C. 78m) is amended by adding at the end the 
14
following: 
15
‘‘(s) DISCLOSURE OF RESEARCH AND DEVELOPMENT 
16
EXPENDITURES BY DRUG MANUFACTURERS.— 
17
‘‘(1) DEFINITIONS.—In this subsection: 
18
‘‘(A) DRUG.—The term ‘drug’ means any 
19
product for which one or more components have 
20
been the subject of any of the following applica-
21
tions filed with the Food and Drug Administra-
22
tion: 
23
‘‘(i) A new drug application (or sup-
24
plemental new drug application) filed 
25
22:05 Apr 08, 2022
H7474
11 
•HR 7474 IH
under subsection (b) or (j) of section 505 
1
of the Federal Food, Drug, and Cosmetic 
2
Act (21 U.S.C. 355). 
3
‘‘(ii) A biologic product application (or 
4
supplemental application) filed under sub-
5
section (a) or (k) of section 351 of the 
6
Public Health Service Act (42 U.S.C. 
7
262). 
8
‘‘(B) DRUG MANUFACTURER ISSUER.—The 
9
term ‘drug manufacturer issuer’ means an 
10
issuer that— 
11
‘‘(i) is required to file an annual re-
12
port with the Commission under subsection 
13
(a); and 
14
‘‘(ii) engages in the development, 
15
manufacture, or marketing of any drug. 
16
‘‘(2) DISCLOSURE.— 
17
‘‘(A) IN GENERAL.—Subject to the other 
18
provisions of this paragraph, the Commission 
19
shall issue rules that require each drug manu-
20
facturer issuer’s annual report under subsection 
21
(a) to include information regarding the drug 
22
manufacturer issuer’s research and development 
23
expenditures with respect to— 
24
‘‘(i) a drug; and 
25
22:05 Apr 08, 2022
H7474
12 
•HR 7474 IH
‘‘(ii) any preliminary research or de-
1
velopment of a drug product or drug sub-
2
stance, as those terms are defined in sec-
3
tion 314.3 of title 21, Code of Federal 
4
Regulations (or any successor regulation) 
5
for which the drug manufacturer issuer 
6
has not submitted an application described 
7
in clause (i) or (ii) of paragraph (1)(A). 
8
‘‘(B) INITIAL
RULES.—The Commission 
9
shall— 
10
‘‘(i) not later than 1 year after the 
11
date of enactment of the Pharmaceutical 
12
Research Transparency Act of 2022, pro-
13
pose initial rules under subparagraph (A); 
14
and 
15
‘‘(ii) not later than 2 years after the 
16
date of enactment described in clause (i), 
17
finalize the rules required under subpara-
18
graph (A). 
19
‘‘(C) REQUIRED
INFORMATION.—The in-
20
formation required under subparagraph (A) 
21
shall include total expenditures, which shall be 
22
disaggregated to each stage of drug research 
23
and development, including— 
24
‘‘(i) basic research; 
25
22:05 Apr 08, 2022
H7474
13 
•HR 7474 IH
‘‘(ii) pre-clinical research; 
1
‘‘(iii) phase I of a clinical investiga-
2
tion of a new drug, as described in section 
3
312.21(a) of title 21, Code of Federal Reg-
4
ulations, or any successor regulation; 
5
‘‘(iv) phase II of a clinical investiga-
6
tion of a new drug, as described in section 
7
312.21(b) of title 21, Code of Federal Reg-
8
ulations, or any successor regulation; 
9
‘‘(v) phase III of a clinical investiga-
10
tion of a new drug, as described in section 
11
312.21(c) of title 21, Code of Federal Reg-
12
ulations, or any successor regulation; and 
13
‘‘(vi) post-market studies or clinical 
14
trials required under section 505(o) of the 
15
Federal Food, Drug, and Cosmetic Act (21 
16
U.S.C. 355(o)). 
17
‘‘(D) LIMITATIONS
CALCULATION.—The 
18
calculation of expenditure information disclosed 
19
under subparagraph (A) shall not include the 
20
following information, although such informa-
21
tion may be disclosed separately: 
22
‘‘(i) Costs incurred in connection with 
23
licensing agreements or acquiring intellec-
24
tual property. 
25
22:05 Apr 08, 2022
H7474
14 
•HR 7474 IH
‘‘(ii) The cost of mergers or acquisi-
1
tions. 
2
‘‘(iii) Any intangible costs, including 
3
estimates, adjustments, and assumptions 
4
related to the risk of failure, or the risk as-
5
sociated with seeking regulatory approval 
6
by the Food and Drug Administration or 
7
another agency. 
8
‘‘(iv) The estimated cost of capital. 
9
‘‘(3) 
CONSULTATION
IN
RULEMAKING.—In 
10
issuing rules under this subsection, the Commis-
11
sion— 
12
‘‘(A) shall consult with the Commissioner 
13
of Food and Drugs and the Director of the Na-
14
tional Institutes of Health; and 
15
‘‘(B) may consult with the head of any 
16
other Federal agency or entity that the Com-
17
mission determines is relevant.’’. 
18
SEC. 4. SEVERABILITY. 
19
If any provision of this Act, an amendment made by 
20
this Act, or the application of any such provision or 
21
amendment to any person or circumstance is held to be 
22
unconstitutional, the remainder of the provisions of this 
23
Act, the amendments made by this Act, and the applica-
24
22:05 Apr 08, 2022
H7474
15 
•HR 7474 IH
tion of such provisions and amendments to any person or 
1
circumstance shall not be affected thereby. 
2
Æ 
22:05 Apr 08, 2022
H7474
